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The common wisdom is that a trachoma program can-
not eliminate ocular chlamydia from a community, just
reduce infection to a level where blindness would be mini-
mal. We describe the success of multiple mass antibiotic
treatments, demonstrating that complete elimination of
infection may be an attainable goal in an area with modest
disease.
T
he World Health Organization (WHO) and a number
of its partners have initiated a program to eliminate
blinding trachoma by the year 2020 (1). Many healthcare
workers feel that attempting to eradicate the ocular strains
of chlamydia that cause trachoma (serovars A, Ba, B, and
C) would be unrealistic and perhaps even unnecessary. A
more attainable goal would be to reduce clinically active
trachoma to some threshold, below which scarring and
blindness would never occur or at least would become so
rare that trachoma would no longer be a major public
health concern (2).
Although in common usage the terms eradication and
elimination can be synonymous, in the field of public
health, they are not(3). Both terms imply reduction of inci-
dence to zero. However, eradication applies to the whole
world, whereas elimination applies to a defined geograph-
ic area and would require further monitoring; in a sense,
elimination can be viewed as a local eradication (4). In
practice, WHO has allowed an even looser usage of the
term elimination: for example, leprosy elimination is
defined as a prevalence of <1 case in 10,000 population,
and tuberculosis elimination is an incidence of <1 case in
100,000 persons per year (5,6). WHO is currently in the
process of defining such a level for trachoma.
Defining an appropriate target for trachoma elimination
is particularly difficult because infection itself is rarely
monitored. Control programs rely almost exclusively on
the clinical examination because the most sensitive
chlamydial tests are expensive and not widely available in
trachoma-endemic areas. The clinical examination is cer-
tainly a reasonable tool to assess whether ocular chlamydia
is hyperendemic in a community. However, the examina-
tion may not be an accurate indicator of infection when
disease prevalence is low, as is often seen after treatment
(7–11). The follicles so characteristic of clinically active
trachoma may linger even when chlamydia is no longer
detectable by using the most sensitive laboratory tech-
niques (7,12). The few studies that have tracked ocular
chlamydial infection using DNA amplification tests sug-
gest that a single mass antibiotic distribution is very effec-
tive, much more successful than a clinical survey would
indicate (9,10).
Could ocular chlamydia be eliminated with multiple
treatments? A mathematical model has shown that period-
ic treatments could theoretically eliminate infection even
without a perfect antibiotic or perfect coverage of the pop-
ulation (13). This same model predicts that annual treat-
ment in areas with moderate amounts of trachoma should
progressively reduce the prevalence of ocular chlamydia in
a community. To date, however, no reports of the efficacy
of multiple annual treatments on infection have been pub-
lished.
The Study
We monitored trachoma prevalence in a village in
Western Nepal for 3 years, using both a clinical grading
system and nucleic acid amplification tests. Three annual
azithromycin (20 mg/kg) treatments were distributed to all
children ages 1–10 years in the village (Figure). All chil-
dren were examined biannually, and the conjunctivae of a
stratified random sample of children were swabbed and
later tested for Chlamydia trachomatis DNA. At the final
visit, 6 months after the last treatment, every child was
examined, and their conjunctivae were swabbed. Before
the first treatment, 39% had active infection determined by
the clinical examination, and an estimated 26% (95% con-
fidence interval [CI] 16% to 35%) were infected with
chlamydia. At the final, May 2001 visit, 7 (4%) of 187
pediatric cases were clinically active. Only 1 child of the
187 (0.5%) had evidence of chlamydia by polymerase
chain reaction. 
Conclusions
This study suggests that local elimination of the ocular
chlamydia that causes trachoma may be possible in a vil-
lage with moderate baseline disease. After three annual
treatments, only one infected child could be identified.
Children are by far the most likely to harbor ocular
chlamydia, and mathematical models imply that they will
be the most difficult group to clear from infection (13,14).
In fact, 1 year after mass azithromycin treatment in a vil-
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1–5 years old than in the rest of the community combined
(9,15). Thus, the nearly complete absence of infection in
children after three treatments implies that elimination is a
possibility. Whether success in this village was due solely
to our treatment program or due in part to a secular trend
in the area, the results are encouraging.
Is elimination of ocular chlamydia necessary? It may
not be for at least three reasons. First, repeat infections are
almost certainly required to cause severe conjunctival
scarring; occasional sporadic infections probably do not
lead to blindness. Second, some investigators hope that if
ocular chlamydia is reduced to a low enough level, the dis-
ease will have difficulty repopulating the community (pop-
ulation biologists call such a prevalence threshold an Allee
effect [16]). While we see no reason for such a phenome-
non a priori, if present, it would certainly establish a
threshold target. Finally, bacterial, viral, and allergic con-
junctivitides can occasionally mimic ocular chlamydia, so
eradication of “clinically active” trachoma will never be
possible.
Trachoma programs have already distributed more than
1 million doses of oral azithromycin, and some villages
have received three annual treatments. How will we know
when to stop? Now is the time to discuss the most appro-
priate target for trachoma programs and the most appropri-
ate definition for trachoma elimination. The common wis-
dom is that complete local elimination of ocular chlamydia
to zero in a defined geographic area is an unattainable goal,
and that programs should settle for reducing the prevalence
of ocular chlamydia to a level where little if any subse-
quent blindness would exist. These results from Nepal
imply that the strict definition of elimination of ocular
chlamydia in children may be an attainable goal, at least in
areas with modest to moderate disease. Whether or not
elimination is necessary is a separate question.
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